{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:44:11Z","timestamp":1792637051422,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013015","name":"Cedars-Sinai Medical Center","doi-asserted-by":"publisher","award":["2022-07"],"award-info":[{"award-number":["2022-07"]}],"id":[{"id":"10.13039\/100013015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.anndiagpath.2023.152226","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T11:47:40Z","timestamp":1699703260000},"page":"152226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Comparative expression of trophoblast cell-surface antigen 2 (TROP2) in the different molecular subtypes of invasive breast carcinoma: An immunohistochemical study of 94 therapy-naive primary breast tumors"],"prefix":"10.1016","volume":"68","author":[{"given":"Richard B.","family":"Mertens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias P.","family":"Makhoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnaz","family":"Dadmanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2023.152226_bb0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.17305\/bb.2022.8874","article-title":"Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes","volume":"23","author":"Vranic","year":"2023","journal-title":"Biomol Biomed"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0010","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0015","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3390\/cancers12113328","article-title":"Trop2: Jack of all trades, master of none","volume":"12","author":"Len\u00e1rt","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0020","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/onc.2012.36","article-title":"Upregulation of Trop-2 quantitatively stimulates human cancer growth","volume":"32","author":"Trerotola","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0025","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbcan.2009.08.001","article-title":"Trop2: a possible therapeutic target for late stage epithelial carcinomas","volume":"1796","author":"Cubas","year":"2009","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications","volume":"6","author":"Shvartsur","year":"2015","journal-title":"Genes Cancer"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0035","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1158\/1078-0432.CCR-04-2107","article-title":"Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors","volume":"11","author":"Huang","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0040","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1186\/1471-2164-12-547","article-title":"Identification of novel targets for breast cancer by exploring gene switches on a genome scale","volume":"12","author":"Wu","year":"2011","journal-title":"BMC Genomics"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yexmp.2012.08.004","article-title":"Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer","volume":"94","author":"Lin","year":"2013","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096993","article-title":"Trop-2 is a determinant of breast cancer survival","volume":"9","author":"Ambrogi","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0055","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0060","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","article-title":"Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"35","author":"Bardia","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0065","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0070","first-page":"759","article-title":"Trop2 is a potential biomarker for the promotion of EMT in human breast cancer","volume":"40","author":"Zhao","year":"2018","journal-title":"Oncol Rep"},{"issue":"4 Suppl","key":"10.1016\/j.anndiagpath.2023.152226_bb0075","first-page":"PS18","article-title":"Loss of Trop2 protein in metaplastic carcinoma of breast by IHC","volume":"81","author":"Yang","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0080","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3892\/mmr.2020.11731","article-title":"Development and characterization of TrMab-6, a novel anti-TROP2 monoclocal antibody for antigen detection in breast cancer","volume":"23","author":"Sayama","year":"2021","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0085","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41523-021-00341-6","article-title":"Oncogene-mediated metabolic gene signature predicts breast cancer outcome","volume":"7","author":"Aslan","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0095","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003468","article-title":"Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10549-022-06602-7","article-title":"Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"195","author":"O\u2019Shaughnessy","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000522206","article-title":"Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors","volume":"89","author":"Dum","year":"2022","journal-title":"Pathobiology"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0110","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1186\/s12885-022-10076-7","article-title":"Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer","volume":"22","author":"Jeon","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0115","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10549-022-06660-x","article-title":"Trophoblast cell surface antigen 2 gene (TACSTD2) expression in primary breast cancer","volume":"194","author":"Vidula","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0120","doi-asserted-by":"crossref","first-page":"33658","DOI":"10.1038\/srep33658","article-title":"Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis","volume":"6","author":"Zeng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0125","doi-asserted-by":"crossref","first-page":"22498","DOI":"10.1038\/s41598-022-27093-y","article-title":"Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancer","volume":"12","author":"Izci","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0130","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s12282-022-01389-3","article-title":"Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance","volume":"29","author":"Zhu","year":"2022","journal-title":"Breast Cancer"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0135","first-page":"15184","article-title":"Changes in intrinsic subtype of breast cancer during tumor progression in the same patient","volume":"8","author":"Kim","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0140","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1158\/0008-5472.CAN-16-2717","article-title":"Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer","volume":"77","author":"Cejalvo","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0145","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41523-022-00439-5","article-title":"Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer - phase 3 ASCENT study subanalysis","volume":"8","author":"Carey","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0150","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0155","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0160","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.annonc.2020.09.004","article-title":"Sacituzumab govitecan in previously treated hormone receptor-positive\/HER2-negative metastatic breast cancer: final results from a phase I\/II, single-arm, basket trial","volume":"31","author":"Kalinsky","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0165","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0170","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0175","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5 Suppl","key":"10.1016\/j.anndiagpath.2023.152226_bb0185","first-page":"GS1","article-title":"Sacituzumab govitecan (SG) vs treatment of physician\u2019s choice (TPC): efficacy by Trop-2 expression in the TROPiCS-02 study of patients (pts) with HR+\/HER2\u2013 metastatic breast cancer (mBC)","volume":"83","author":"Rugo","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0190","series-title":"Breast tumours","article-title":"WHO classification of tumours editorial board","year":"2019"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0195","series-title":"WHO classification of tumours editorial board. Breast tumours","first-page":"82","article-title":"Invasive breast carcinoma: general overview","author":"Rakha","year":"2019"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0200","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0205","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research","volume":"15","author":"Koo","year":"2016","journal-title":"J Chiropr Med"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0210","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1053\/j.seminoncol.2020.05.005","article-title":"The evolving management of metastatic triple negative breast cancer","volume":"47","author":"Malhotra","year":"2020","journal-title":"Semin Oncol"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0215","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2147\/OTT.S354048","article-title":"TROP2 as patient-tailoring but not prognostic marker for breast cancer","volume":"15","author":"Liu","year":"2022","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0220","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.3390\/cancers14235936","article-title":"Trop-2 as a therapeutic target in breast cancer","volume":"14","author":"Sakach","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0225","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1158\/1535-7163.MCT-16-0431","article-title":"RN927C, a site-specific Trop-2 antibody-drug conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models","volume":"15","author":"Strop","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0230","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fonc.2020.00118","article-title":"Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan (SN-38), in ovarian cancer","volume":"10","author":"Perrone","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0235","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41598-020-58009-3","article-title":"Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan","volume":"10","author":"Zeybek","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0240","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.3390\/cancers14194789","article-title":"Trophoblast cell surface antigen 2 (TROP2) as a predictive bio-marker for the therapeutic efficacy of sacituzumab govitecan in adenocarcinoma of the esophagus","volume":"14","author":"Hoppe","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0245","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.951589","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"12","author":"Cheng","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0255","doi-asserted-by":"crossref","first-page":"560","DOI":"10.18632\/oncotarget.27342","article-title":"Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas","volume":"11","author":"Lopez","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0260","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.18632\/oncotarget.27766","article-title":"Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer","volume":"11","author":"Cardillo","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0265","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0270","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","article-title":"Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer","volume":"66","author":"Shastry","year":"2022","journal-title":"Breast J"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0275","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.21037\/atm-21-1103","article-title":"Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?","volume":"9","author":"Santi","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0280","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/his.14852","article-title":"TROP2, androgen receptor, and PD-L1 status in histological subtypes of high-grade metaplastic breast carcinomas","volume":"82","author":"Chartier","year":"2023","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0285","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1634\/theoncologist.2017-0398","article-title":"Early and locally advanced metaplastic breast cancer: presentation and survival by receptor status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014","volume":"23","author":"Schroeder","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.anndiagpath.2023.152226_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101054","article-title":"Metaplastic breast cancer: treatment and prognosis by molecular subtype","volume":"14","author":"Hu","year":"2021","journal-title":"Transl Oncol"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913423001247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913423001247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:36:00Z","timestamp":1761078960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913423001247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":57,"alternative-id":["S1092913423001247"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2023.152226","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative expression of trophoblast cell-surface antigen 2 (TROP2) in the different molecular subtypes of invasive breast carcinoma: An immunohistochemical study of 94 therapy-naive primary breast tumors","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2023.152226","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152226"}}